← Back to Clinical Trials
Recruiting NCT07193823

NCT07193823 Sexual Dysfunction in Women With Multiple Sclerosis (MS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07193823
Status Recruiting
Phase
Sponsor Ege University
Condition Multiple Sclerosis
Study Type OBSERVATIONAL
Enrollment 140 participants
Start Date 2024-07-16
Primary Completion 2025-10

Eligibility & Interventions

Sex Female only
Min Age 25 Years
Max Age 50 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 140 participants in total. It began in 2024-07-16 with a primary completion date of 2025-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Sexual dysfunction in women with multiple sclerosis (MS) is an important yet often overlooked problem. The primary objective of this study is to investigate the prevalence of sexual dysfunction in female patients diagnosed with MS. The secondary objective is to evaluate the relationship between sexual dysfunction and fatigue, depression, anxiety, overactive bladder symptoms, and cognitive dysfunction. For this purpose, the following validated instruments will be used: the Female Sexual Function Index (FSFI) to assess sexual dysfunction, the Brief International Cognitive Assessment for MS (BICAMS) to evaluate cognitive function, the Hospital Anxiety and Depression Scale (HADS) to assess depression and anxiety, the Fatigue Severity Scale (FSS) to measure fatigue, and the Overactive Bladder Questionnaire (OAB-V8) to evaluate overactive bladder symptoms.

Eligibility Criteria

Inclusion Criteria: * Female patients aged 25-50 years * Literate and able to comprehend written and spoken instructions * Diagnosed with relapsing-remitting form of multiple sclerosis * Having a continuous/regular sexual partner * Expanded Disability Status Scale (EDSS) score ≤ 5 * At least 3 months since the last relapse * Sexually active within the past 3 months * Spasticity level \< grade 2 according to the Modified Ashworth Scale Exclusion Criteria: * Pregnancy * Illiteracy or inability to understand spoken or written instructions * Absence of a continuous/regular sexual partner * Expanded Disability Status Scale (EDSS) score \> 5 * Not sexually active within the past 3 months * Spasticity level ≥ grade 2 according to the Modified Ashworth Scale

Contact & Investigator

Central Contact

Merve Dokumaci, Resident doctor

✉ dokumacimerve@gmail.com

📞 +905435088428

Principal Investigator

Yesim Akkoc, M.D., Prof

STUDY DIRECTOR

Ege University Faculty of Medicine, Department of Physical Medicine and Rehabilitation

Frequently Asked Questions

Who can join the NCT07193823 clinical trial?

This trial is open to female participants only, aged 25 Years or older, up to 50 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07193823 currently recruiting?

Yes, NCT07193823 is actively recruiting participants. Contact the research team at dokumacimerve@gmail.com for enrollment information.

Where is the NCT07193823 trial being conducted?

This trial is being conducted at Izmir, Turkey (Türkiye).

Who is sponsoring the NCT07193823 clinical trial?

NCT07193823 is sponsored by Ege University. The principal investigator is Yesim Akkoc, M.D., Prof at Ege University Faculty of Medicine, Department of Physical Medicine and Rehabilitation. The trial plans to enroll 140 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology